UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000005959
Receipt No. R000007018
Scientific Title Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication
Date of disclosure of the study information 2011/07/12
Last modified on 2019/08/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication
Acronym Clinical study on therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans
Scientific Title Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication
Scientific Title:Acronym Clinical study on therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans
Region
Japan

Condition
Condition Patients with combined lumbar spinal stenosis and arteriosclerosis obliterans
Classification by specialty
Orthopedics
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The prospective study is performed with the aim to evaluate the therapeutic effects of prostaglandin from the viewpoint of administration method and duration by administering the drug to patients with combined lumbar spinal stenosis and arteriosclerosis obliterans (peripheral arterial disease) who exhibit intermittent claudication, which tends to increase in aging society.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The Japanese Orthopaedic Association (JOA) score
Key secondary outcomes Age, sex, affected period, biochemical examination of blood, details of treatment (number and frequency of infusions, concomitant drug therapy, block therapy, and other conservative therapies), SF-36, VAS

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 3
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Prostaglandin for injection (alprostadil) group: 60 mcg of prostaglandin for injection is intravenously administered once a week or more. This therapy is repeated 10 times or more.
Interventions/Control_2 Ripple injection (alprostadil Injection) group: 10 mcg of ripple injection is administered intravenously once a week or more. This treatment is repeated 10 times or more.
Interventions/Control_3 Conventional treatment group
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria The subjects are patients who meet all of the following inclusion criteria and are able to provide informed consent.
1) Male and female patients aged 20 years or older.
2) Patients who are diagnosed with lumbar spinal stenosis based on X-ray and MRI findings and are undergoing conservative treatment.
3) Patients who are diagnosed with arteriosclerosis obliterans (peripheral arterial disease) Fontaine classification I or II.
4) Patients who understand the objectives of this study and provide informed consent.
Key exclusion criteria The patients who meet any of the following exclusion criteria are excluded.
1) Patients who have ethical difficulties due to special consideration required for them or their family.
2) Patients with diabetes, chronic renal failure, etc. who are suspected to have a complication of peripheral nerve disorder or circulatory disorder.
3) Patients who are receiving administration of anticoagulant, etc.
4) Patients who have a history of surgical treatment for the spine/spinal cord.
5) Patients who have problematic infection.
6) Patients who do not understand the objectives of this study.
Target sample size 300

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name MASATO SATO,M.D.,Ph.D.
Organization Tokai University School of Medicine
Division name Department of Orthopaedic Surgery
Zip code
Address 143,Shimokasuya,Isehara,Kanagawa,259-1193,Japan
TEL 0463-93-1121
Email

Public contact
Name of contact person
1st name
Middle name
Last name MASATO SATO,M.D.,Ph.D.
Organization Tokai University School of Medicine
Division name Department of Orthopaedic Surgery
Zip code
Address 143,Shimokasuya,Isehara,Kanagawa,259-1193,Japan
TEL 0463-93-1121
Homepage URL
Email

Sponsor
Institute Tokai University Hospital
Department of Orthopaedic Surgery
Institute
Department

Funding Source
Organization Tokai University Hospital
Department of Orthopaedic Surgery
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2011 Year 07 Month 12 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2010 Year 04 Month 12 Day
Date of IRB
2010 Year 11 Month 04 Day
Anticipated trial start date
2010 Year 11 Month 04 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2011 Year 07 Month 11 Day
Last modified on
2019 Year 08 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007018

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.